HIV / AIDS

Primary care physicians and advanced practice providers are responsible for the majority of people seeking medical care in the United States, yet there is a gap in discussing sexual health for those who are at risk of HIV or other sexually-transmitted diseases.

“The combination of the 2 drugs was shown in this trial to be noninferior to the standard 3-drug regimen,” said Jean Michel Molina, MD, PhD, lead investigator of Merck’s islatravir/doravirine study.

This fungal infection is an example of either being a treatable ailment or one that can cause severe disease and death depending on access to diagnostic and treatment resources.

Investigators looked at people living with HIV (PLWH) and the impact of this form of medication on potential cardiovascular events.

Here's a recap of our most newsworthy coverage of the CROI 2023 conference.

At the CROI conference, AELIX Therapeutics announced positive topline results for a phase 2a clinical trial.

“Patients deserve more than just viral suppression,” said Harmony Garges, MD, chief medical officer of ViiV Healthcare.

“We should test everybody,” said Charles Béguelin, noting that the vast majority of hepatitis D infections go undetected.

Here is an overview of highly anticipated HIV trial data ViiV Healthcare will share next week at the CROI 2023 conference.

Among male couples, HIV PrEP usage is suboptimal. Lingering stigma may be preventing men who have sex with men from using PrEP, even when in a relationship with an HIV-positive partner.

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.

The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

Clinicians can make room for infrequent treatment options as patients enjoy their daily lives.

This therapy is the first of a new class of antiretrovirals, and it is indicated for people with multi-drug resistance, intolerance, or safety considerations.

A central portal to support clinical practice for patients with or at risk for HIV was launched.

Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.

A new CDC report highlights another health-related area where interruptions occurred due to the pandemic, but data suggests both improved rapidly.

Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Triumeq PD, the first dispersible single tablet regimen with dolutegravir, for children living with HIV.

For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the implications of recent data regarding the use of fostemsavir and ibalizumab.

The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.

Daniel R. Kuritzkes, MD, describes how the unique mechanism of lenacapavir allows clinicians to maintain viral inhibition over time.

Joseph Eron, MD, and Monica Gandhi, MD, MPH, describe the obstacles to treatment efficacy with the available treatment options.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.